Company intelligence / Profile preview

eddii

New York, New York, United Stateseddiihealth.com ↗

Ownership: Private
Development stage: Other

Overview

eddii has demonstrated clinical benefit in a randomized controlled trial involving children with T1D using Dexcom CGMs. The study showed a statistically significant improvement of approximately five percentage points in Time In Range (TIR), equating to about an extra hour and a half per day spent within optimal glucose levels[4]. The company’s platform has expanded from pediatric to adult diabetes care, now offering virtual appointments with licensed endocrinologists for both populations[2][4].

Therapeutic areas: Endocrinology
Modalities: Device (app-based digital therapeutic)Non-pharmacological therapy (behavioral intervention via gamification and education)
Industry: Digital Health Medical Devices

Partnerships

Dexcom (integration of Dexcom CGM devices into the app)

Beyond the preview

Go deeper on eddii.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eddii.

Explore the full profile